AYUSH-64 was repurposed after scientific evidence generated from 7 clinical studies across India
Sri Sri Tattva, Bengaluru-based health & wellness, FMCG brand, has introduced the AYUSH-64 tablets, which is been recognised by the Ministry of Ayush for being effective in the treatment of mild to moderate COVID-19 patients.
It has obtained technology transfer from the National Research & Development Corporation and will manufacture and distribute it nationally and internationally.
It was launched in the presence of Padma Shri Vaidya Rajesh Kotecha, Honourable Secretary, Ministry of Ayush, Arvind Varchaswi, Managing Director, Sri Sri Tattva, Padma Bhushan Vaidya Devendra Triguna Ji, President, All India Ayurveda Congress, Bhushan Patwardhan, Former Vice-Chairman, University Grants Commission (UGC), Dr N Srikanth, Director General, The Central Council for Research in Ayurvedic Sciences (CCRAS), Rajiv Vasudevan, Founder AyurVAID Hospitals and Vikas Chauhan, Co-founder, 1 mg.
AYUSH-64 was repurposed after scientific evidence generated from 7 clinical studies across India. It has been identified as a potential adjunct to standard care in the management of asymptomatic, mild and moderate COVID-19 to improve the clinical recovery and quality of life through robust clinical trials conducted in the country. The in-silico study done on AYUSH-64 showed that about 35 out of 36 of its Phyto-constituents have a high binding affinity against the COVID-19 virus.
AYUSH-64 is an addition to the range of immunity-building products that the brand is already championing. These include Sri Sri Tattva Kabasura Kudineer tablets, Amruth, Turmeric Plus, Shakti Drops, and Tulasi Arka and Chyawanprash.